These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 8133004)

  • 41. An economic analysis of the current universal 2-dose measles-mumps-rubella vaccination program in the United States.
    Zhou F; Reef S; Massoudi M; Papania MJ; Yusuf HR; Bardenheier B; Zimmerman L; McCauley MM
    J Infect Dis; 2004 May; 189 Suppl 1():S131-45. PubMed ID: 15106102
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Administration of measles-mumps-rubella vaccination with other childhood schedule vaccines.
    Heath TC; Burgess MA; O'Brien ED
    Commun Dis Intell; 1998 Aug; 22(8):159. PubMed ID: 9735551
    [No Abstract]   [Full Text] [Related]  

  • 43. Immunogenicity and efficacy of one dose measles-mumps-rubella (MMR) vaccine at twelve months of age as compared to monovalent measles vaccination at nine months followed by MMR revaccination at fifteen months of age.
    Ceyhan M; Kanra G; Erdem G; Kanra B
    Vaccine; 2001 Aug; 19(31):4473-8. PubMed ID: 11483273
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Emergency department vaccination of preschool-age children during a measles outbreak.
    Schlenker TL; Risk I; Harris H
    Ann Emerg Med; 1995 Sep; 26(3):320-3. PubMed ID: 7661422
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Measles, mumps, and rubella vaccine coverage in 2 year old children in East Lancashire--better than it looks.
    Clark A; Marshall R
    Commun Dis Public Health; 1999 Jan; 2(1):50-3. PubMed ID: 10462897
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sentinel surveillance shows small decline in MMR coverage.
    Commun Dis Rep CDR Wkly; 1998 Sep; 8(36):317, 320. PubMed ID: 9782644
    [No Abstract]   [Full Text] [Related]  

  • 47. Reactogenicity and immunogenicity of a new combined measles-mumps-rubella vaccine: results of a multicentre trial. The Cooperative Group for the Study of MMR vaccines.
    Crovari P; Gabutti G; Giammanco G; Dentico P; Moiraghi AR; Ponzio F; Soncini R
    Vaccine; 2000 Jun; 18(25):2796-803. PubMed ID: 10812221
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparative evaluation of two combined measles-mumps-rubella vaccines based on AIK and Edmonston- Zagreb strains of measles virus.
    Mirchamsy H; Nilforoushan MA; Shafyi A; Razavi J; Ashtiani MP; Youssofi I; Sassani A; Fateh G; Nassiri S
    Kitasato Arch Exp Med; 1991 Sep; 64(2-3):141-7. PubMed ID: 1811112
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Providing MMR vaccine to children.
    Orenstein WA; Plotkin S
    Minn Med; 1991 Mar; 74(3):7-8. PubMed ID: 2030684
    [No Abstract]   [Full Text] [Related]  

  • 50. Two dose MMR vaccine schedule.
    Burgess MA
    J Paediatr Child Health; 1994 Oct; 30(5):453. PubMed ID: 7833088
    [No Abstract]   [Full Text] [Related]  

  • 51. Antibody response following measles-mumps-rubella vaccine under conditions of customary use.
    Brunell PA; Weigle K; Murphy MD; Shehab Z; Cobb E
    JAMA; 1983 Sep; 250(11):1409-12. PubMed ID: 6887461
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Does a modified vaccination schedule protect better against measles?].
    van 't Spijker C; Rümke HC
    Ned Tijdschr Geneeskd; 1994 Nov; 138(48):2400-5. PubMed ID: 7990988
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Reactogenicity and immunogenicity of a new live attenuated combined measles, mumps and rubella vaccine in healthy children.
    Usonis V; Bakasenas V; Kaufhold A; Chitour K; Clemens R
    Pediatr Infect Dis J; 1999 Jan; 18(1):42-8. PubMed ID: 9951979
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Response to measles-mumps-rubella vaccine in children on dialysis.
    Schulman SL; Deforest A; Kaiser BA; Polinsky MS; Baluarte HJ
    Pediatr Nephrol; 1992 Mar; 6(2):187-9. PubMed ID: 1571219
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Risk of seizures after measles-mumps-rubella immunization.
    Griffin MR; Ray WA; Mortimer EA; Fenichel GM; Schaffner W
    Pediatrics; 1991 Nov; 88(5):881-5. PubMed ID: 1945626
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Expanded programme on immunization. Vaccine efficacy in a measles immunization programme.
    Wkly Epidemiol Rec; 1992 Jul; 67(30):224-7. PubMed ID: 1498025
    [No Abstract]   [Full Text] [Related]  

  • 57. Previous exposure to measles, mumps, and rubella--but not vaccination during adolescence--correlates to the prevalence of pancreatic and thyroid autoantibodies.
    Lindberg B; Ahlfors K; Carlsson A; Ericsson UB; Landin-Olsson M; Lernmark A; Ludvigsson J; Sundkvist G; Ivarsson SA
    Pediatrics; 1999 Jul; 104(1):e12. PubMed ID: 10390298
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prevalence of hepatitis B markers and measles, mumps, and rubella antibodies among Jewish refugees from the former Soviet Union.
    Hurie MB; Gennis MA; Hernandez LV; Dindzans VJ; Davis JP
    JAMA; 1995 Mar 22-29; 273(12):954-6. PubMed ID: 7884955
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP).
    McLean HQ; Fiebelkorn AP; Temte JL; Wallace GS;
    MMWR Recomm Rep; 2013 Jun; 62(RR-04):1-34. PubMed ID: 23760231
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Marin M; Broder KR; Temte JL; Snider DE; Seward JF;
    MMWR Recomm Rep; 2010 May; 59(RR-3):1-12. PubMed ID: 20448530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.